Targeting of AUF1 to vascular endothelial cells as a novel anti-aging therapy
Targeting of AUF1 to vascular endothelial cells as a novel anti-aging therapy作者机构：National Center for International Research of Biological Targeting Diagnosis and Therapy Guangxi Key Laboratory of Biological Targeting Diagnosis andTherapy Research'Collaborative lnnovatton Center for Targeting Tumor Diagnosis and TherapyGuangxi Medical UniversityNanningGuangxiChina
出 版 物：《Journal of Geriatric Cardiology》 (老年心脏病学杂志（英文版）)
年 卷 期：2017年第14卷第8期
页 面：515-523页
核心收录：
学科分类：0710[理学-生物学] 081702[工学-化学工艺] 1002[医学-临床医学] 07[理学] 08[工学] 0817[工学-化学工程与技术] 071003[理学-生理学]
基 金：This work was supported by grants from the Guangxi Natural Science Foundation (No. 2015GXNSFAA139217 and 2016GXNSFAA380231) a grant from The Scientific Research Fund of Guangxi Education Department (No. YB2014057) entitled "AU-rich region connecting factor 1 targeted vascular endothelial cells for anti-aging" a grant from the Youth Foundation in Guangxi Medical Univer- sity (No. GXMUYSF201328) a grant from the Undergraduate Innovative plan in Guangxi (No. 201510598012) and a grant from the Guangxi Education Department Grant entitled "Innovation Project of Guangxi Graduate Educa- tion"
主 题：Aging AU-rich region connecting factor 1 PEGylated immunoliposomes Vascular endothelial ceils
摘 要：Background Inhibition of aging of vascular endothelial cells （VECs） may delay aging and prolong life. The goal of this study was to prepare anti-CD31 monoclonal antibody conjugated PEG-modified liposomes containing the AU-rich region connecting factor 1 （AUF1） gene （CD31-PILs-AUF1） and to explore the effects of targeting CD31-PILs-AUF1 to aging VECs. Methods The mean particle sizes of various PEGylated immunoliposomes （PILs） were measured using a Zetasizer Nano ZS. Gel retardation assay was used to confirm whether PILs had encapsulated the AUF1 plasmid successfully. Fluorescence microscopy and flow cytometry were used to quantify binding of CD31-PILs-AUF1 to target cells. Flow cytometry was also used to analyze the cell cycles of aging bEnd3 cells treated with CD31-PILs-AUF1. We also developed an aging mouse model by treating mice with D-galactose. Enzyme-linked immunosorbent assay （ELISA） was used to evaluate the levels of interleuldn-6 （IL-6） and tumor necrosis factor-or （TNF-ct）. The malondialdehyde （MDA） and the superoxide dismutase （SOD） levels were detected by commercial kits. Hematoxylin-eosin （HE） staining was used to determine whether treatment with CD31-PILs-AUF 1 was toxic to the mice. Results CD31-PILs-AUF 1 specifically could targeted bEnd3 VECs and increased the percentage of cells in the S and G2/M phases of aging bEnd3 cells. ELISA showed that content of the IL-6 and TNF-ct decreased in CD31-PILs-AUF1 group. The level of SOD increased, whereas MDA decreased in the CD31-PILs-AUF1 group. Additionally, CD31-PILs-AUF 1 was not toxic to the mice. Conclusion CD31-PILs-AUF 1 targets VECs and may delay their senescence.
维普期刊数据库